FUNDACIO PRIVADA MON CLINIC BARCELONA

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG

Not Applicable

Not yet recruiting

Conditions: Portal Hypertension
Chronic Liver Disease (CLD)
Cirrhosis

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-07

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 20

Registration Number: NCT06863012

Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study

Recruiting

Conditions: Respiratory Synctial Virus
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Exacerbation of COPD

First Posted Date: 2024-12-16

Last Posted Date: 2025-02-26

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 892

Registration Number: NCT06735612

Locations: 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain

Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor

Not Applicable

Recruiting

Conditions: Glaucoma Eye

Interventions: Device: Monitoring with contact lens sensor

First Posted Date: 2024-09-23

Last Posted Date: 2025-03-06

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 53

Registration Number: NCT06607705

Locations: 🇪🇸
Institut Català de Retina, Barcelona, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain

ANTES B+ Clinical Trial

Phase 4

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Drug: Brimica
Drug: Duaklir
Drug: Ultibro
Drug: Ulunar
Drug: Xoterna
Drug: Anoro
Drug: Laventair
Drug: Spiolto Respimat
Drug: Yanimo
Drug: Foradil
Drug: Broncoral
Drug: Formoterol stada
Drug: Oxis
Drug: Formatris
Drug: Formoterol Aldo
Drug: Onbrez
Drug: Oslif
Drug: Hirobriz
Drug: Striverdi
Drug: Beglan
Drug: Betamican
Drug: Inaspir
Drug: Serevent
Drug: Soltel
Drug: Eklira
Drug: Bretaris
Drug: Seebri
Drug: Tovanor
Drug: Enurev
Drug: Spiriva
Drug: Tavulus
Drug: Sirkava
Drug: Braltus
Drug: Gregal
Drug: Incruse
Drug: Rolufta

First Posted Date: 2024-02-28

Last Posted Date: 2024-03-05

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 1028

Registration Number: NCT06282861

Locations: 🇪🇸
Hospital Clínic Barcelona, Barcelona, Catalunya, Spain

Effects of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) Therapy on miRNAs Expression and Absolute Microvascular Resistance by Continuous Thermodilution in ST-segment Elevation Myocardial Infarction (STEMI) Patients: PiCSO-STEMI TRIAL

Not Applicable

Not yet recruiting

Conditions: Anterior Myocardial Infarction

Interventions: Device: PiCSO Impulse System
Procedure: Percutaneous Coronary Intervention (PCI)

First Posted Date: 2022-12-09

Last Posted Date: 2023-02-22

Lead Sponsor: Fundacio Privada Mon Clinic Barcelona

Target Recruit Count: 46

Registration Number: NCT05644925

Home Terms & Conditions Privacy Policy